Breaking
Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit RulingAlpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026Takeda's TAK-881 Shows Positive Phase 2/3 Results for Primary Immunodeficiency Disease Treatment
🇺🇸 FDA

Targeted Therapy

Page 1 • 1 item

Articles about Targeted Therapy

Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
NewsOncology - Advanced Breast CancerMay 4, 2026

Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer

Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.

Dr. Laura Bennett